EGFR and non-small cell lung carcinoma: It has previously been shown that erlotinib-induced NF-κB-mediated IL6 expression promotes survival of non-small cell lung cancer cells treated with this EGFR tyrosine kinase inhibitor, and it was suggested that this adaptive response to erlotinib treatment could ultimately promote acquired resistance to this drug [43].